Clinical trial · Observational
Real-World Study of the Safety and Efficacy of Surufatinib in the Treatment of Neuroendocrine Tumors
NCT07780539CI-TRIAL-00123186not yet recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Prior clinical trials have demonstrated promising efficacy and manageable safety of surufatinib in neuroendocrine tumors (NETs). This real-world study aims to evaluate the clinical efficacy and safety of surufatinib in patients with NETs, providing additional real-world evidence to support clinical application, guide novel therapeutic strategies, and ultimately improve patient outcomes.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neuroendocrine (NE) Tumors | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Surufatinib Administration | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- surufatinib
- description
- Surufatinib therapy
- interventionNames
- Drug: Surufatinib Administration
Primary outcomes (1)
- measure
- Progression-free survival (PFS)
- timeFrame
- approximately up to 24 months
- description
- the time from the date of first study treatment to the date of first documented tumor progression (assessed according to RECIST version 1.1) or death due to any cause, whichever occurs first.
Secondary outcomes (1)
- measure
- Objective response rate (ORR)
- timeFrame
- approximately up to 24 months
- description
- the proportion of patients with complete response (CR) or partial response (PR) according to RECIST version 1.1 criteria in the analysis population.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with pathologically or cytologically confirmed neuroendocrine tumors; * At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1; * Life expectancy ≥ 12 weeks; * Adequate organ and bone marrow function Exclusion Criteria: * Participation in other drug clinical trials with investigational drug treatment within the past 4 weeks; * History of other malignancies within the past 5 years, except for curatively resected basal cell or squamous cell carcinoma of the skin, or cervical carcinoma in situ; * Patients with contraindications to surufatinib (e.g., active bleeding, ulcer, intestinal perforation, intestinal obstruction, medically uncontrolled hypertension, grade III-IV cardiac dysfunction, within 30 days after major surgery, severe hepatic or renal impairment, etc.); * Presence of any disease or condition that affects drug absorption, or inability to take surufatinib orally; * Any condition deemed by the investigator as unsuitable for study drug treatment.
References
Publications (0)
Data not yet available
No reference posted for this study.